Provided by Tiger Fintech (Singapore) Pte. Ltd.

Lineage Cell Therapeutics Inc

0.5200
+0.0000
Post-market: 0.52000.00000.00%19:51 EDT
Volume:875.50K
Turnover:461.14K
Market Cap:118.75M
PE:-5.59
High:0.5478
Open:0.5201
Low:0.5160
Close:0.5200
Loading ...

Company Profile

Company Name:
Lineage Cell Therapeutics Inc
Exchange:
AMEX
Establishment Date:
1990
Employees:
74
Office Location:
2173 Salk Avenue,Suite 200,Carlsbad,California,United States
Zip Code:
92008
Fax:
- -
Introduction:
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers ANP1, an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of debilitating hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Immunomic Therapeutics, Inc., for the treatment of glioblastoma multiforme. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.

Directors

Name
Position
Alfred D. Kingsley
Chairman of the Board
Brian M. Culley
Chief Executive Officer and Director
Angus C. Russell
Director
Anula Jayasuriya
Director
Deborah Andrews
Director
Dipti Amin
Director
Don M. Bailey
Director
Michael H. Mulroy
Director
Neal C. Bradsher
Director

Shareholders

Name
Position
Brian M. Culley
Chief Executive Officer and Director
Gary S. Hogge
Senior Vice President of Clinical & Medical Affairs
Jill A. Howe
Chief Financial Officer
George A. Samuel III
General Counsel and Corporate Secretary